Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Research Characteristics
The only trial FDA staff were able to find about the effectiveness of using BPC-157 to treat ulcerative colitis was a meeting abstract reporting on the results of a study using 46 people in which the peptide was given as an enema, not as an injection
Analysis of application in patients with digestive system diseases BPC 157 (Body Protection Compound 157) is a synthetic peptide composed of 15 amino acids, which has significant gastrointestinal protection, anti-inflammatory and tissue repair properties
However, in the pivotal Phase IIb trial, it failed to demonstrate statistically significant weight loss compared to placebo at the primary endpoint, leading the developer (Metabolic Pharmaceuticals Ltd.) to terminate the commercial program
US$ 20.91
US$ 28.30
US$ 25.04
US$ 28.71
US$ 29.92
